AMD had something of a mixed year, but more was happening with its CPUs compared to the firm’s graphics cards.

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in ...